XOMA Royalty Corporation (XOMA)
NASDAQ:XOMA
Want to see XOMA full AI Analyst Report?
XOMA Stock Chart & Stats
$39.71
$0.08(0.31%)
At close: 4:00 PM EST
$39.71
$0.08(0.31%)
Day’s Range― - ―
52-Week Range$22.29 - $42.81
Previous CloseN/A
Volume8.24K
Average Volume (3M)53.64K
Market Cap
$524.47M
Enterprise Value$552.60M
Total Cash (Recent Filing)$94.96M
Total Debt (Recent Filing)$124.73M
Price to Earnings (P/E)20.9
Beta1.45
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.65
Shares Outstanding12,541,030
10 Day Avg. Volume49,949
30 Day Avg. Volume53,642
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)4.60
Price to Sales (P/S)41.01
P/FCF Ratio166.54
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue15.25
Enterprise Value/Gross Profit16.35
Enterprise Value/Ebitda13.20
Forecast
1Y Price Target
$42.67Price Target Upside7.45% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)1.12
Revenue Forecast (FY)$68.55M
Bulls Say, Bears Say
Bulls Say
Cost Discipline And ProfitabilityAnalyst notes disciplined operating expense management that supports an emerging path to sustained profitability as royalty streams scale.
Partnership Expansion And AcquisitionsAnalyst highlights expansion of the Takeda partnership and continued strategic acquisitions as drivers that can broaden the company's partnered asset base and enhance future transactional and royalty opportunities.
Royalty Income GrowthAnalyst views XOMA's maturing royalty model as positioned to generate increasing royalty income from commercial and late‑stage partnered assets through expected milestone payments and future royalties.
Bears Say
Clinical Setback RiskAnalyst points out that Rezolute's ersodetug did not achieve statistically significant reductions in hypoglycemia events, increasing clinical and commercial uncertainty for that partnered program.
Regulatory UncertaintyAnalyst highlights that Gossamer's planned meeting with the FDA to discuss a path forward introduces regulatory uncertainty for the related partnered asset and could affect future milestones.
Revenue Timing VolatilityAnalyst warns that milestone payments from partnered programs can arrive unevenly, creating revenue volatility and making short‑term revenue less predictable.
XOMA Royalty Corporation News
XOMA FAQ
What was XOMA Royalty Corporation’s price range in the past 12 months?
XOMA Royalty Corporation lowest stock price was $22.29 and its highest was $42.81 in the past 12 months.
What is XOMA Royalty Corporation’s market cap?
XOMA Royalty Corporation’s market cap is $524.47M.
When is XOMA Royalty Corporation’s upcoming earnings report date?
XOMA Royalty Corporation’s upcoming earnings report date is Jul 30, 2026 which is in 68 days.
How were XOMA Royalty Corporation’s earnings last quarter?
XOMA Royalty Corporation released its earnings results on Apr 30, 2026. The company reported $0.173 earnings per share for the quarter, beating the consensus estimate of $0.168 by $0.005.
Is XOMA Royalty Corporation overvalued?
According to Wall Street analysts XOMA Royalty Corporation’s price is currently Undervalued.
Does XOMA Royalty Corporation pay dividends?
XOMA Royalty Corporation does not currently pay dividends.
What is XOMA Royalty Corporation’s EPS estimate?
XOMA Royalty Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XOMA Royalty Corporation have?
XOMA Royalty Corporation has 12,541,030 shares outstanding.
What happened to XOMA Royalty Corporation’s price movement after its last earnings report?
XOMA Royalty Corporation reported an EPS of $0.173 in its last earnings report, beating expectations of $0.168. Following the earnings report the stock price went down -0.122%.
Which hedge fund is a major shareholder of XOMA Royalty Corporation?
Currently, no hedge funds are holding shares in XOMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
XOMA Royalty Corporation Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$42.67 (7.45% Upside)
$42.67 (7.45% Upside)
Hedge Fund Trend
Increased
By 53.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.28%
12-Months-Change
Fundamentals
Return on Equity
30.21%
Trailing 12-Months
Asset Growth
27.78%
Trailing 12-Months
Company Description
XOMA Royalty Corporation
XOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
XOMA Company Deck
XOMA Earnings Call
Q4 2026
0:00 / 0:00
XOMA Stock 12 Month Forecast
Average Price Target
$42.67
▲(7.45% Upside)
Technical Analysis
Ocugen
―
Corvus Pharmaceuticals
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
14.86% Insiders
18.24% Mutual Funds
34.26% Other Institutional Investors
24.04% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---